|
Commerce ministry extends RoDTEP Scheme for pharma exporters till March 2026
|
|
Shardul Nautiyal, Mumbai
October 01 , 2025
|
|
|
In a major decision aimed at supporting India's pharma export sector, the ministry of commerce & industry has officially extended the Remission of Duties and Taxes on Exported Products (RoDTEP) Scheme till March 31, 2026.
The notification has been issued on September 30, 2025 by the Directorate General of Foreign Trade (DGFT), under the authority of the Foreign Trade (Development and Regulation) Act, 1992, and the provisions of the Foreign Trade Policy (FTP) 2023.
The RoDTEP Scheme, which was earlier set to expire on September 30, 2025, will now continue to apply to exports from Domestic Tariff Area (DTA) units, Advance Authorisation (AA) holders, Special Economic Zone (SEZ) units, and Export Oriented Units (EOUs) until the end of the current financial year.
The extension ensures that pharma exporters continue to receive remission of embedded central, state, and local duties and taxes. These include taxes on electricity, fuel, and logistics services, which are often non-recoverable and add to the cost burden for exporters.
The DGFT has confirmed that existing RoDTEP rates and item eligibility will remain unchanged. Exporters can refer to the official website of DGFT (www.dgft.gov.in) under the section “Regulations > RoDTEP” for detailed lists of eligible items along with applicable rates and per-unit value caps. These are separately listed in Appendix 4R for DTA units and Appendix 4RE for AA, SEZ, and EOU units.
The existing RoDTEP rates, as notified, shall continue to apply for all export items. The operation of the scheme shall, however, remain subject to the budgetary framework provided under Para 4.54 of FTP 2023, so that the remissions during the financial year are managed within the approved allocation.
This move reflects the government’s sustained commitment to enhancing the global competitiveness of Indian pharma exports by reducing the burden of taxes. It is especially timely as exporters navigate a dynamic global trade environment marked by shifting supply chains, evolving market demands, and recovery from recent global disruptions.
Pharma exporters and industry stakeholders have welcomed the extension, calling it a positive step towards maintaining policy stability and boosting India’s foreign trade prospects in the near term.
|
|
|
|
|
|
|
|
TOPICS
|
The Food and Drug Administration (FDA), Maharashtra, has issued a public advisory urging citizens to report any misleadi ...
|
|
|
|
|